Bharat Parenterals Ltd
Bharat Parenterals Q4 FY25 earnings call: Revenue & Margins
Q4 FY25 earnings call: what management guided on revenue, margins and order book.
The short version
Innoxel is expected to operationally break even in FY '26 with INR70 crores revenue, with significant revenue growth anticipated in subsequent years as more products commercialize. Innoxel's revenue is expected to reach around INR 70 crores in FY '26, targeting operational breakeven with 30%+ net margins in subsequent years as commercial revenues grow.
From Bharat Parenterals Ltd's Q4 FY25 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Innoxel is expected to operationally break even in FY '26 with INR70 crores revenue, with significant revenue growth anticipated in subsequent years as more products commercialize.
- The CDMO division has potential to run 40-50 programs concurrently, indicating capacity for robust growth with continued product additions.
- Varenyam Healthcare aims for INR60-65 crores revenue with 30-35% EBITDA margin, targeting branded generics in domestic hospital and prescription markets.
- Domestic standalone business maintains roughly a 50:50 split between institutional (government tenders) and non-institutional sales, supporting steady demand.
- New manufacturing facility expansions and ongoing phase-3 capacity addition at Innoxel in 12-18 months will facilitate scaling output.
2 more points from Bharat Parenterals Ltd's call on revenue
Pro opens every point from 15K+ earnings calls
Profitability & Margins
See what Bharat Parenterals Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- No planned capex at Innoxel Lifesciences for the current financial year, except for one skid installation related to a client project, which is not considered direct capex by Bharat Parenterals.
- Varenyam Bio Lifesciences has an ongoing capex project estimated between INR120-150 crores; around INR30 crores spent so far with construction underway and expected operational readiness by 2027.
- Bharat Parenterals has completed significant past capex, including INR250 crores at Innoxel (mostly land, plant & machinery), with no immediate further capital injection planned there.
2 more points from Bharat Parenterals Ltd's call on capex
Pro opens every point from 15K+ earnings calls
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Bharat Parenterals Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- Bharat Parenterals is working on products therapeutically agnostic, focusing on therapeutic injectables, 505b2 molecules, and oral liquids.
- The addressable market for products already signed is upwards of a few billion dollars.
- Innoxel has developed around 20 products, with 7 to 10 out-licensed or tied up.
- The company aims to be the first or second entrant in these markets, some requiring market creation.
- The CDMO pipeline has a healthy split of approximately 60% injectables and 40% oral liquids.
- Revenue visibility is expected to grow as products get commercialized; profit share from marketed products will significantly improve the bottom line.
2 more points from Bharat Parenterals Ltd's call on order book
Pro opens every point from 15K+ earnings calls
Bharat Parenterals Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹100 Cr, net loss ₹8 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Bharat Parenter.'s management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Jubilant Pharmo (Q4 FY25)
Q4 FY25 consolidated revenue grew 10% YoY to Rs. Key concall takeaways from Jubilant Pharmova Ltd's Q4 FY25 earnings call — and how it ranks against sector…
- Anuh Pharma Ltd (Q4 FY25)
For Q4 FY 2025, operating revenue was ₹198.14 crore, a 2.24% year-on-year increase from ₹193.63 crore in Q4 FY 2024 (derived from annual total revenue…
- Themis Medicare (Q4 FY25)
71.70 Cr, down 27% YoY from Rs. Key concall takeaways from Themis Medicare Ltd's Q4 FY25 earnings call — and how it ranks against sector peers.
- Lincoln Pharma. (Q4 FY25)
Revenue: $1.2 billion, representing a 5% increase year-on-year. Key concall takeaways from Lincoln Pharmaceuticals Ltd's Q4 FY25 earnings call — and how it…
Arthneeti Pro · Annual
Bharat Parenterals Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Bharat Parenterals Ltd Q4 FY25 results?
Innoxel is expected to operationally break even in FY '26 with INR70 crores revenue, with significant revenue growth anticipated in subsequent years as more products commercialize. Innoxel's revenue is expected to reach around INR 70 crores in FY '26, targeting operational breakeven with 30%+ net margins in subsequent years as commercial revenues grow.
What is Bharat Parenterals Ltd share price analysis?
Bharat Parenterals Ltd currently shows a neutral. The stock trades at a P/E of N/A with a market cap of ₹1,007 Cr. Investors should review the full earnings analysis for detailed insights.
Is Bharat Parenterals Ltd planning capital expenditure?
No planned capex at Innoxel Lifesciences for the current financial year, except for one skid installation related to a client project, which is not considered direct capex by Bharat Parenterals.
Keep Bharat Parenterals Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.